Latest Biotech News

Sanofi revealed data from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS), detailing why the program missed endpoints and prompting...

Biotech’s public markets showed renewed activity as Agomab Therapeutics and Eikon Therapeutics raised capital in recent IPOs, and industry reporting highlighted four drugmakers that went public in...

Formation Bio detailed its AI‑native drug development model and growth strategy, with CTO Dan Neil explaining how the company applies data, software and clinical execution to accelerate assets...

Rice University secured up to $24.8 million from ARPA‑H to advance bioprinted kidney tissue under the PRINT program, funding a multi‑year effort to develop transplantable, vascularized renal...

A CNIO‑ and CIEMAT‑led team described an innovative gene‑editing strategy that exploits tumors with high oncogene amplification, using CRISPR‑Cas9 to selectively target cancer cells overloaded...

Researchers published Nature Communications data showing a bacteriophage‑antibiotic combination eradicated refractory peritoneal dialysis‑related peritonitis caused by Klebsiella pneumoniae in...

Telehealth company Hims & Hers announced it will stop offering a compounded version of Novo Nordisk’s Wegovy after escalating legal threats and regulatory scrutiny from U.S. authorities. Novo...

uniQure said it has paused mid‑ and high‑dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced dose‑limiting toxicities, including grade 3 liver enzyme...

Public markets saw renewed interest in biotech this week as multiple drugmakers completed IPOs, collectively raising close to $1 billion. Companies including Agomab Therapeutics and Eikon...

Priovant Therapeutics, a Roivant spinout, reported that brepocitinib significantly outperformed placebo in a Phase 2 trial for cutaneous sarcoidosis, producing marked lesion clearance in the...

Bayer disclosed Phase 3 results showing asundexian, a Factor XIa inhibitor, reduced risk of secondary stroke by 26% without increasing clinically relevant bleeding. The firm reported the data as...

Adaptive Biotechnologies projected meaningful growth for its minimal residual disease (MRD) business in 2026, forecasting 20–22% revenue expansion and anticipating ClonoSeq test volume to rise...

Rice University secured up to $24.8 million from ARPA‑H to develop bioprinted kidney tissues as part of a multi‑year effort to address the organ donor shortfall. The award funds a consortium led...

A team published in Nature Communications a method that decodes phantom limb motor commands directly from intraneural recordings, providing a new control signal source for neuroprosthetics. The...

Researchers reported in Nature Communications that combining bacteriophages with antibiotics eradicated refractory Klebsiella pneumoniae peritonitis in a preclinical peritoneal dialysis model. The...

A Max Planck Institute team introduced ADAPT‑MS, an informatics framework that trains clinical classifiers on discovery proteomics data and adapts models at the individual‑sample level, aiming to...

Telehealth firm Hims & Hers announced it will stop offering a compounded version of Novo Nordisk’s Wegovy after escalating legal and regulatory pressure. The company moved to halt distribution...

The Department of Health and Human Services announced it will abandon the proposed 340B rebate pilot after hospitals and providers sued to block the plan. Providers argued the pilot would create...

Gene‑therapy developer uniQure paused mid‑ and high‑dose cohorts in its Fabry disease AAV trial after two patients experienced dose‑limiting liver toxicities, including grade 3 transaminase...

Public markets showed renewed appetite for biotech this week as Eikon Therapeutics priced an upsized IPO that will generate approximately $381 million and several other drugmakers completed...